FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519118088> ?p ?o ?g. }

• W2519118088 abstract "Background Genotype® MTBDRsl (MTBDRsl) is a rapid DNA‐based test for detecting specific mutations associated with resistance to fluoroquinolones and second‐line injectable drugs (SLIDs) in Mycobacterium tuberculosis complex. MTBDRsl version 2.0 (released in 2015) identifies the mutations detected by version 1.0, as well as additional mutations. The test may be performed on a culture isolate or a patient specimen, which eliminates delays associated with culture. Version 1.0 requires a smear‐positive specimen, while version 2.0 may use a smear‐positive or ‐negative specimen. We performed this updated review as part of a World Health Organization process to develop updated guidelines for using MTBDRsl. Objectives To assess and compare the diagnostic accuracy of MTBDRsl for: 1. fluoroquinolone resistance, 2. SLID resistance, and 3. extensively drug‐resistant tuberculosis, indirectly on a M. tuberculosis isolate grown from culture or directly on a patient specimen. Participants were people with rifampicin‐resistant or multidrug‐resistant tuberculosis. The role of MTBDRsl would be as the initial test, replacing culture‐based drug susceptibility testing (DST), for detecting second‐line drug resistance. Search methods We searched the following databases without language restrictions up to 21 September 2015: the Cochrane Infectious Diseases Group Specialized Register; MEDLINE; Embase OVID; Science Citation Index Expanded, Conference Proceedings Citation Index‐Science, and BIOSIS Previews (all three from Web of Science); LILACS; and SCOPUS; registers for ongoing trials; and ProQuest Dissertations & Theses A&I. We reviewed references from included studies and contacted specialists in the field. Selection criteria We included cross‐sectional and case‐control studies that determined MTBDRsl accuracy against a defined reference standard (culture‐based DST, genetic sequencing, or both). Data collection and analysis Two review authors independently extracted data and assessed quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool. We synthesized data for versions 1.0 and 2.0 separately. We estimated MTBDRsl sensitivity and specificity for fluoroquinolone resistance, SLID resistance, and extensively drug‐resistant tuberculosis when the test was performed indirectly or directly (smear‐positive specimen for version 1.0, smear‐positive or ‐negative specimen for version 2.0). We explored the influence on accuracy estimates of individual drugs within a drug class and of different reference standards. We performed most analyses using a bivariate random‐effects model with culture‐based DST as reference standard. Main results We included 27 studies. Twenty‐six studies evaluated version 1.0, and one study version 2.0. Of 26 studies stating specimen country origin, 15 studies (58%) evaluated patients from low‐ or middle‐income countries. Overall, we considered the studies to be of high methodological quality. However, only three studies (11%) had low risk of bias for the reference standard; these studies used World Health Organization (WHO)‐recommended critical concentrations for all drugs in the culture‐based DST reference standard. MTBDRsl version 1.0 Fluoroquinolone resistance: indirect testing, MTBDRsl pooled sensitivity and specificity (95% confidence interval (CI)) were 85.6% (79.2% to 90.4%) and 98.5% (95.7% to 99.5%), (19 studies, 2223 participants); direct testing (smear‐positive specimen), pooled sensitivity and specificity were 86.2% (74.6% to 93.0%) and 98.6% (96.9% to 99.4%), (nine studies, 1771 participants, moderate quality evidence). SLID resistance: indirect testing, MTBDRsl pooled sensitivity and specificity were 76.5% (63.3% to 86.0%) and 99.1% (97.3% to 99.7%), (16 studies, 1921 participants); direct testing (smear‐positive specimen), pooled sensitivity and specificity were 87.0% (38.1% to 98.6%) and 99.5% (93.6% to 100.0%), (eight studies, 1639 participants, low quality evidence). Extensively drug‐resistant tuberculosis: indirect testing, MTBDRsl pooled sensitivity and specificity were 70.9% (42.9% to 88.8%) and 98.8% (96.1% to 99.6%), (eight studies, 880 participants); direct testing (smear‐positive specimen), pooled sensitivity and specificity were 69.4% (38.8% to 89.0%) and 99.4% (95.0% to 99.3%), (six studies, 1420 participants, low quality evidence). Similar to the original Cochrane review, we found no evidence of a significant difference in MTBDRsl version 1.0 accuracy between indirect and direct testing for fluoroquinolone resistance, SLID resistance, and extensively drug‐resistant tuberculosis. MTBDRsl version 2.0 Fluoroquinolone resistance: direct testing, MTBDRsl sensitivity and specificity were 97% (83% to 100%) and 98% (93% to 100%), smear‐positive specimen; 80% (28% to 99%) and 100% (40% to 100%), smear‐negative specimen. SLID resistance: direct testing, MTBDRsl sensitivity and specificity were 89% (72% to 98%) and 90% (84% to 95%), smear‐positive specimen; 80% (28% to 99%) and 100% (40% to 100%), smear‐negative specimen. Extensively drug‐resistant tuberculosis: direct testing, MTBDRsl sensitivity and specificity were 79% (49% to 95%) and 97% (93% to 99%), smear‐positive specimen; 50% (1% to 99%) and 100% (59% to 100%), smear‐negative specimen. We had insufficient data to estimate summary sensitivity and specificity of version 2.0 (smear‐positive and ‐negative specimens) or to compare accuracy of the two versions. A limitation was that most included studies did not consistently use the World Health Organization (WHO)‐recommended concentrations for drugs in the culture‐based DST reference standard. Authors' conclusions In people with rifampicin‐resistant or multidrug‐resistant tuberculosis, MTBDRsl performed on a culture isolate or smear‐positive specimen may be useful in detecting second‐line drug resistance. MTBDRsl (smear‐positive specimen) correctly classified around six in seven people as having fluoroquinolone or SLID resistance, although the sensitivity estimates for SLID resistance varied. The test rarely gave a positive result for people without drug resistance. However, when second‐line drug resistance is not detected (MTBDRsl result is negative), conventional DST can still be used to evaluate patients for resistance to the fluoroquinolones or SLIDs. We recommend that future work evaluate MTBDRsl version 2.0, in particular on smear‐negative specimens and in different settings to account for different resistance‐causing mutations that may vary by strain. Researchers should also consider incorporating WHO‐recommended critical concentrations into their culture‐based reference standards." @default.
• W2519118088 created "2016-09-23" @default.
• W2519118088 creator A5009308092 @default.
• W2519118088 creator A5021801489 @default.
• W2519118088 creator A5044462827 @default.
• W2519118088 creator A5056139536 @default.
• W2519118088 creator A5077397137 @default.
• W2519118088 creator A5079771128 @default.
• W2519118088 date "2016-09-08" @default.
• W2519118088 modified "2023-10-04" @default.
• W2519118088 title "GenoType^® MTBDR<i>sl</i> assay for resistance to second-line anti-tuberculosis drugs" @default.
• W2519118088 cites W1610203956 @default.
• W2519118088 cites W163647522 @default.
• W2519118088 cites W1727928392 @default.
• W2519118088 cites W1759161252 @default.
• W2519118088 cites W1863711781 @default.
• W2519118088 cites W1965917206 @default.
• W2519118088 cites W1977881210 @default.
• W2519118088 cites W1989511460 @default.
• W2519118088 cites W1993644690 @default.
• W2519118088 cites W1993768310 @default.
• W2519118088 cites W1999495563 @default.
• W2519118088 cites W2004090960 @default.
• W2519118088 cites W2004143136 @default.
• W2519118088 cites W2013707717 @default.
• W2519118088 cites W2020661238 @default.
• W2519118088 cites W2027357554 @default.
• W2519118088 cites W2028488795 @default.
• W2519118088 cites W2030144417 @default.
• W2519118088 cites W2033888443 @default.
• W2519118088 cites W2034437593 @default.
• W2519118088 cites W2046417607 @default.
• W2519118088 cites W2048078358 @default.
• W2519118088 cites W2060640683 @default.
• W2519118088 cites W2074415800 @default.
• W2519118088 cites W2077433872 @default.
• W2519118088 cites W2079990719 @default.
• W2519118088 cites W2086134690 @default.
• W2519118088 cites W2087906885 @default.
• W2519118088 cites W2090070686 @default.
• W2519118088 cites W2090542083 @default.
• W2519118088 cites W2103876802 @default.
• W2519118088 cites W2106577966 @default.
• W2519118088 cites W2107638293 @default.
• W2519118088 cites W2108560866 @default.
• W2519118088 cites W2110084229 @default.
• W2519118088 cites W2112704710 @default.
• W2519118088 cites W2114428335 @default.
• W2519118088 cites W2118913806 @default.
• W2519118088 cites W2123300483 @default.
• W2519118088 cites W2124628939 @default.
• W2519118088 cites W2126727011 @default.
• W2519118088 cites W2128022675 @default.
• W2519118088 cites W2128057974 @default.
• W2519118088 cites W2129341611 @default.
• W2519118088 cites W2131631509 @default.
• W2519118088 cites W2133515801 @default.
• W2519118088 cites W2134698288 @default.
• W2519118088 cites W2135400982 @default.
• W2519118088 cites W2135468821 @default.
• W2519118088 cites W2139686915 @default.
• W2519118088 cites W2140993748 @default.
• W2519118088 cites W2141210320 @default.
• W2519118088 cites W2148900601 @default.
• W2519118088 cites W2148980855 @default.
• W2519118088 cites W2154954684 @default.
• W2519118088 cites W2155498694 @default.
• W2519118088 cites W2157072930 @default.
• W2519118088 cites W2160571788 @default.
• W2519118088 cites W2163483340 @default.
• W2519118088 cites W2164057360 @default.
• W2519118088 cites W2164559367 @default.
• W2519118088 cites W2177680624 @default.
• W2519118088 cites W2315468075 @default.
• W2519118088 cites W2323035211 @default.
• W2519118088 cites W2334479968 @default.
• W2519118088 cites W2337887044 @default.
• W2519118088 cites W2401695647 @default.
• W2519118088 cites W2409478631 @default.
• W2519118088 cites W2411506910 @default.
• W2519118088 cites W2428730651 @default.
• W2519118088 cites W3020992444 @default.
• W2519118088 cites W4253057716 @default.
• W2519118088 doi "https://doi.org/10.1002/14651858.cd010705.pub3" @default.
• W2519118088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5034505" @default.
• W2519118088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27605387" @default.
• W2519118088 hasPublicationYear "2016" @default.
• W2519118088 type Work @default.
• W2519118088 sameAs 2519118088 @default.
• W2519118088 citedByCount "43" @default.
• W2519118088 countsByYear W25191180882017 @default.
• W2519118088 countsByYear W25191180882018 @default.
• W2519118088 countsByYear W25191180882019 @default.
• W2519118088 countsByYear W25191180882020 @default.
• W2519118088 countsByYear W25191180882021 @default.
• W2519118088 countsByYear W25191180882022 @default.
• W2519118088 countsByYear W25191180882023 @default.
• W2519118088 crossrefType "journal-article" @default.
• W2519118088 hasAuthorship W2519118088A5009308092 @default.
• W2519118088 hasAuthorship W2519118088A5021801489 @default.

• next